The Effectiveness of Gout ’Treat-to-Target’ Booklet in Improving Gout Outcome

Early Phase 1

• Conditions: Gout.; Gout; Gouty tophi; Gouty tophi of heart; Gouty tophi of ear; Gouty elbow; Gouty tophi of foot; Gouty tophi of hand; Gouty tophi of olecranon bursa; M10.9

• Registration Number: IRCT20220317054316N2
• Lead Sponsor: niversiti Teknologi MARA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Pending
• Sex: Male
• Target Recruitment: 72

Inclusion Criteria

adult age 18 and more,
Fullfill ACR/EULAR 2015 gout criteria,
patient referred to Rheumatology clinic UiTM for the management of =1 of the condition such as inter-critical gout with frequent flare (=4 flare a year) and/or; polyarticular gout and/or; chronic advanced gout (with or without tophi) and/or; SUA level > 480 ?mol/L.
Able to speak and read in Malay
agree to participate and sign written consent

Exclusion Criteria

patients with contraindications to Allopurinol and Febuxostat (severe heart failure, end stage renal failure and severe hepatic impairment of Child’s C liver cirrhocis);
patients with dementia

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.gout flare. Timepoint: before intervention, week-8, week-16. Method of measurement: number of episodes, duration and severity (Likert scale 1 - 10 with 10 most severe).;Laboratory: serum uric acid, creatinine, liver function test. Timepoint: Baseline, week-8, week-16. Method of measurement: blood taking and using machine in the laboratory.;Disability index. Timepoint: baseline, week-8, week-16. Method of measurement: Questionnaire: Health Assessment Questionnaire Disability Index (HAQ-DI).